Arrowhead Pharmaceuticals, Inc. Aktie News

Arrowhead Pharmaceuticals, Inc. ( ARWR ) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome November 18, 2025 1:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Bruce Given - Chief Medical Scientist Andy Da...

FDA approved Plozasiran (now REDEMPLO™) on November 18, 2025, for reducing triglycerides in adults with FCS, the first siRNA therapy for this rare disease. ARWR boasts a diversified RNAi pipeline targeting liver, lung, muscle, CNS, and obesity, with multiple late-stage candidates and strong efficacy data. The company maintains a robust cash runway of 24 months, supported by partnerships and mil...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 peopl...

The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals' drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the health regulator's website showed on Tuesday.

A busy period is ahead for Arrowhead Pharmaceuticals on regulatory, legal, and clinical fronts. The PDUFA date with the FDA for plozasiran is tomorrow, and an approval should be expected, but competitor Ionis is suing for infringement of its '333 patent. Ionis' olezarsen recently generated very strong phase 3 results in severe hypertriglyceridemia patients and these results offer positive read-...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fiscal year ended September 30, 2025. Webcast and Conference Call Details Investors may access a live audio webcast on the Events and Presentations page unde...

Sold 138,263 shares of Arrowhead Pharmaceuticals; Estimated transaction value: $3,039,518 Post-trade stake: 473,951 shares valued at $16.35 million as of September 30, 2025 Arrowhead Pharmaceuticals now accounts for 2.94% of fund AUM, which places it outside the fund's top five holdings

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: American Heart Association (AHA) Scientific Sessions 2025 – November 7-10, 2025 Title: Rationale and Design: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Zodasiran in Adolescents...